BioSpace News Archive

Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug application to begin a Phase I trial of BMF-219,

Croom Medical has produced over 20,000 Additive Implants as of September 2021 at its Additive Manufacturing center of excellence.

Elite HRT, a leading force in hormone replacement therapy wellness, has just published guidance on how to approach this treatment.

Inventiva announced a series of recruitments with a view to accelerate the development of its lead drug candidate lanifibranor for the treatment of NASH.

aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit,

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit on Monday, September 20, 2021 at 1:15 PM Eastern Time.

Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen (14) new employees.

Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 400,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

Agenus today presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO) Virtual Conference 2021 in an abstract titled Balstilimab

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), announced that the results of the Phase 2 study in Chinese patients with advanced cholangiocarcinoma were released today at the European Society for Medical Oncology (ESMO) Congress 2021 (E-poster # 50P).